Clin Mol Hepatol.
2023 Apr;29(2):345-348. 10.3350/cmh.2023.0094.
The prime time for management of hepatocellular carcinoma in Hong Kong
- Affiliations
-
- 1Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
- 2State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China
- KMID: 2541413
- DOI: http://doi.org/10.3350/cmh.2023.0094
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Personalized management of cirrhosis by non-invasive tests of liver fibrosis
- Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
- Steatotic liver disease: Know your enemies
- Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective
- The Growing Problem of Radiologist Shortage: Hong Kong’s Perspective
